SV-BR-1-GM + Low dose cyclophosphamide + Interferon Inoculation + retifanlimab
Phase 1/2Recruiting 0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Breast Cancer
Conditions
Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer, Breast Cancer Metastatic
Trial Timeline
Mar 16, 2018 → Nov 30, 2028
NCT ID
NCT03328026About SV-BR-1-GM + Low dose cyclophosphamide + Interferon Inoculation + retifanlimab
SV-BR-1-GM + Low dose cyclophosphamide + Interferon Inoculation + retifanlimab is a phase 1/2 stage product being developed by BriaCell Therapeutics for Breast Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT03328026. Target conditions include Breast Cancer, Breast Neoplasm, Metastatic Breast Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Breast Cancer were approved
Approved (20) Terminated (4) Active (0)
Hype Score Breakdown
Clinical
9
Activity
15
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03328026 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Breast Cancer